HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

DMP 728

structure in first source; RN given refers to the monomethane sulfate

Also Known As:

DMP-728; DMP728; XL 118; XL-118; XL118; cyclic(D-2-aminobutyryl-N(2)-methyl-L-arginylglycyl-L-aspartyl-3-(aminomethyl)benzoic acid); cyclic(D-2-aminobutyryl-N-2-methyl-L-arginyl-glycyl-L-aspartyl-3-aminomethylbenzoic acid)methanesulfonic acid salt

Networked: 7 relevant articles (4 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Thrombosis (Thrombus) 04/01/1997 - "DMP728 was shown to be significantly effective in inhibiting ex vivo platelet aggregation and in inhibiting thrombosis at 0.3 to 1.0 mg/kg PO. " 01/01/1994 - "The antithrombotic efficacy of DMP 728 was examined in vitro and in vivo after IV administration at different doses in various models of arterial thrombosis. " 01/01/1994 - "The goals of the present study were to determine the antiplatelet and antithrombotic efficacies of DMP 728 in various arterial thrombosis models. " 01/01/1998 - "DMP728 demonstrated a relatively greater affinity for activated than for unactivated human platelets, which might be essential for attaining an optimal thrombus/blood (target/background) distribution ratio and the optimal detection of small clots (i.e. " 04/01/1997 - "Thrombus formation (platelet-rich aggregate with fibrous coating and a few erythrocytes) by anodal electrolytic stimulation (300 microA) to the intimal surface of the right carotid artery was initiated 120 minutes after oral DMP728 administration and continued for 180 minutes. "
2.	Carotid Artery Thrombosis 04/01/1997 - "The present study was undertaken to determine the oral antithrombotic efficacy of a potent and specific platelet GPIIb/ IIIa antagonist, DMP728, in an electrically induced carotid artery thrombosis model in dogs. " 05/01/1999 - "In vivo antithrombotic efficacy of GPIIb/IIIa receptor antagonists (m7E3, MK-383 and DMP-728) was studied with respect to their ex vivo platelet inhibition in heparinized platelet-rich plasma (hPRP) and citrated platelet-rich plasma (cPRP) using a canine model of carotid artery thrombosis. " 04/01/1994 - "We examined DMP 728 [(cyclic[D-2-amino-butyryl-N2-methyl-L-arginyl-glycyl-L-aspartyl-3-(a min o- methyl-benzoic acid], methanesulfonic acid salt], a cyclic peptidomimetic, GPIIb/IIIa receptor antagonist, for prevention of thrombosis and rethrombosis in a canine model of carotid artery thrombosis. "

Related Drugs and Biologics

1.	Fibrinolytic Agents (Antithrombotic Agents)
2.	tirofiban (Aggrastat)
3.	Streptokinase
4.	Tissue Plasminogen Activator (Alteplase)
5.	Platelet Membrane Glycoprotein IIb
6.	Benzoic Acid (Ucephan)
7.	Anistreplase (APSAC)
8.	Plasminogen Activators (Plasminogen Activator)
9.	Glycoproteins (Glycoprotein)
10.	methanesulfonic acid (methanesulfonate)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)